Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there is significant uncertainty regarding the level and timing of sales of Arestvyr™ and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. We cannot predict with certainty if or when SIGA will begin recognizing profit on the sale thereof and there can be no assurance that any profits received by SIGA and paid to us will be significant. Furthermore, SIGA has filed an appeal with the Delaware Supreme Court challenging aspects of the Court of Chancery decision, and there can be no assurances that the decision will not be reversed or that the remedy will not otherwise be modified. In addition, we cannot predict how long the appeal will delay the receipt of payments, if any, from SIGA. Further, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for all of our product candidates, and with FDA's August 2012 clinical hold of SparVax®, it is unclear when, if ever, we can re-initiate human clinical trials for that product candidate. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

-- Tables Follow -- PHARMATHENE, INC.CONSOLIDATED BALANCE SHEETSDecember 31,20122011ASSETSCurrent assets:Cash and cash equivalents

$
2,701,517$   11,236,771Accounts receivable (billed)

2,432,6414,424,442Unbilled accounts receivable

4,114,4423,021,208Prepaid expenses and other current assets

547,245830,585Restricted cash

-100,000Total current assets'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
(Date:7/11/2014)... WEST PALM BEACH, Fla. , July 11, 2014 ... wide variety of high-quality peptides that are used solely ... online. To honor two successful years in business, Maxim ... Performance LLC, has just launched a new and updated ... addition, the research blog section has been updated with ...
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2
... Scientific Group Inc. (OTC Bulletin Board: BMSN)( ... wholly owned subsidiary, announced today they have jointly submitted ... Research and Materiel Command (USAMRMC) for consideration of funding ... (ASCs) harvested from liposuction for treating Traumatic Brain Injury ...
... Calif., May 4 Pulse Systems announced today that ... facility through the Structured Finance Group at Fifth Third ... million term loan and a $1.5 million revolving working ... arrangement of this scope in today,s challenging banking environment ...
... May 4 Arno Therapeutics, Inc. (OTC Bulletin Board: ... today announced that it has voluntarily filed a Form ... order to deregister its common stock under the Securities ... effective immediately, Arno,s obligation to file periodic and other ...
Cached Biology Technology:Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury 2Pulse Systems Announces New $8.5 Million Credit Facility 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3
(Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... to 15 percent of couples of childbearing age struggle with ... new hope with Cornell researchers' identification of a mutation in ... is the first time that a dominant mutation that leads ... researchers say they can now look for similar mutations in ...
... research in France on patients diagnosed with cryptococcosis ... patients infected by HIV and who are profoundly ... 5 2007 in PLoS Medicine, uncovers parameters associated ... sex and the infecting serotype. In light of ...
... a combination of radiation seed implants and external beam ... disease 15 years following their treatment, according to a ... Oncology*Biology*Physics, the official journal of ASTRO. , This study ... Institute. Doctors wanted to look at the combination of ...
Cached Biology News:Researchers find gene mutation that causes infertility in male mice 2New recommendations against a major opportunistic infection -- cryptococcosis 2New recommendations against a major opportunistic infection -- cryptococcosis 3
... derivatives that have mutations in both the ... genes, which greatly enhances disulfide bond formation ... expression in Origami(DE3) yielded 10-fold more active ... overall expression levels were similar (1). Origami ...
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... CELLection Dynabeads (4.5 m) coated with the ... EpCAM and DNase Releasing Buffer. For ... tumour cells directly from blood, bone marrow ... enriched from bone marrow. Enriched cells are ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Biology Products: